Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial

Peng-Peng Xu; Di Fu; Jian-Yong Li; Jian-Da Hu; Xin Wang; Jian-Feng Zhou; Hao Yu; Xia Zhao; Yao-Hui Huang; Lu Jiang; Feng Liu; Li-Ping Su; Zhuo-Wen Chen; Qing-Shu Zeng; Jie-Ping Chen; Mei-Yun Fang; Jun Ma; Ting Liu; Yong-Ping Song; Kang Yu; Yan Li; Lu-Gui Qiu; Xie-Qun Chen; Jian Gu; Jin-Song Yan; Ming Hou; Heng-Ye Huang; Li Wang; Shu Cheng; Yang Shen; Hui Xiong; Sai-Juan Chen; Wei-Li Zhao

doi:10.1016/s2352-3026(19)30051-1

Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial

The Lancet Haematology ◽

10.1016/s2352-3026(19)30051-1 ◽

2019 ◽

Vol 6 (6) ◽

pp. e328-e337 ◽

Cited By ~ 8

Author(s):

Peng-Peng Xu ◽

Di Fu ◽

Jian-Yong Li ◽

Jian-Da Hu ◽

Xin Wang ◽

...

Keyword(s):

Cell Lymphoma ◽

Controlled Trial ◽

B Cell Lymphoma ◽

Phase 3 ◽

Multicentre Phase ◽

Large B Cell Lymphoma ◽

Dose Optimisation ◽

Randomised Controlled ◽

Large B Cell ◽

Anthracycline Dose

Download Full-text

Faculty Opinions recommendation of CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14204.471770 ◽

2006 ◽

Author(s):

Louis Diehl

Keyword(s):

Randomised Controlled Trial ◽

B Cell ◽

Cell Lymphoma ◽

Controlled Trial ◽

Young Patients ◽

B Cell Lymphoma ◽

Good Prognosis ◽

Large B Cell Lymphoma ◽

Randomised Controlled ◽

Large B Cell

Download Full-text

Faculty Opinions recommendation of CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14204.471704 ◽

2006 ◽

Author(s):

Michael Williams

Keyword(s):

Randomised Controlled Trial ◽

B Cell ◽

Cell Lymphoma ◽

Controlled Trial ◽

Young Patients ◽

B Cell Lymphoma ◽

Good Prognosis ◽

Large B Cell Lymphoma ◽

Randomised Controlled ◽

Large B Cell

Download Full-text

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(17)30444-8 ◽

2017 ◽

Vol 18 (8) ◽

pp. 1076-1088 ◽

Cited By ~ 43

Author(s):

Annalisa Chiappella ◽

Maurizio Martelli ◽

Emanuele Angelucci ◽

Ercole Brusamolino ◽

Andrea Evangelista ◽

...

Keyword(s):

Cell Lymphoma ◽

B Cell Lymphoma ◽

High Dose Chemotherapy ◽

High Dose ◽

Open Label ◽

Phase 3 ◽

Large B Cell Lymphoma ◽

Dose Dense ◽

Randomised Controlled ◽

Large B Cell

Download Full-text

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

The Lancet Oncology ◽

10.1016/s1470-2045(06)70664-7 ◽

2006 ◽

Vol 7 (5) ◽

pp. 379-391 ◽

Cited By ~ 1363

Author(s):

Michael Pfreundschuh ◽

Lorenz Trümper ◽

Anders Österborg ◽

Ruth Pettengell ◽

Marek Trneny ◽

...

Keyword(s):

Randomised Controlled Trial ◽

B Cell ◽

Cell Lymphoma ◽

Controlled Trial ◽

Young Patients ◽

B Cell Lymphoma ◽

Good Prognosis ◽

Large B Cell Lymphoma ◽

Randomised Controlled ◽

Large B Cell

Download Full-text

Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

Advances in Therapy ◽

10.1007/s12325-020-01603-8 ◽

2021 ◽

Vol 38 (4) ◽

pp. 1889-1903

Author(s):

Yuqin Song ◽

Hui Zhou ◽

Huilai Zhang ◽

Wei Liu ◽

Yuerong Shuang ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Large B Cell Lymphoma ◽

Parallel Group ◽

Large B Cell

Download Full-text

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30935-5 ◽

2019 ◽

Vol 20 (5) ◽

pp. 649-662 ◽

Cited By ~ 41

Author(s):

Andrew Davies ◽

Thomas E Cummin ◽

Sharon Barrans ◽

Tom Maishman ◽

Christoph Mamot ◽

...

Keyword(s):

Gene Expression ◽

B Cell ◽

Gene Expression Profiling ◽

Expression Profiling ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Open Label ◽

Phase 3 ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

Annals of Oncology ◽

10.1093/annonc/mdx022 ◽

2017 ◽

Vol 28 (5) ◽

pp. 1042-1049 ◽

Cited By ~ 8

Author(s):

T. Petrella ◽

C. Copie-Bergman ◽

J. Brière ◽

R. Delarue ◽

F. Jardin ◽

...

Keyword(s):

Elderly Patients ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Cell Of Origin ◽

Phase 3 ◽

Large B Cell Lymphoma ◽

Large B Cell ◽

Bcl2 Expression

Download Full-text

Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial

British Journal of Haematology ◽

10.1111/bjh.16691 ◽

2020 ◽

Author(s):

Mary Gleeson ◽

Nicholas Counsell ◽

David Cunningham ◽

Anthony Lawrie ◽

Laura Clifton‐Hadley ◽

...

Keyword(s):

Cancer Research ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 3 ◽

Cancer Research Institute ◽

Large B Cell Lymphoma ◽

National Cancer Research Institute ◽

The Uk ◽

Large B Cell

Download Full-text

MYC Rearrangement Positive Large B-Cell Lymphoma Patients Can Be Treated Successfully with R-CHOP Plus Lenalidomide: Results of a Multicentre Phase II HOVON Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3296686 ◽

2018 ◽

Author(s):

Martine Chamuleau ◽

Coreline N. Burggraaff ◽

Marcel Nijland ◽

Katerina Bakunina ◽

Rogier Mous ◽

...

Keyword(s):

B Cell ◽

Phase Ii ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Multicentre Phase ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.07.238 ◽

2018 ◽

Vol 18 ◽

pp. S293-S294

Author(s):

Olalekan O. Oluwole ◽

Michael R. Bishop ◽

Christian Gisselbrecht ◽

Leo I. Gordon ◽

Marie José Kersten ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

Randomized Study ◽

B Cell Lymphoma ◽

Standard Of Care ◽

Phase 3 ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text